The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction
Table 1
Baseline characteristics.
Total collective
Ischemic HFrEF ()
Nonischemic HFrEF ()
value
Age, years (IQR)
65.6 (57.1-70.7)
66.6 (57.7-70.8)
61.9 (56.4-70.7)
0.094
Male gender, (%)
84 (75.7)
47 (82.5)
37 (69.1)
0.098
BMI, kg/m2 (IQR)
28.1 (24.6-31.3)
28.7 (25.3-31.9)
27.5 (24.1-30.8)
0.994
Diabetes mellitus, (%)
42 (38.2)
23 (41.1)
19 (32.5)
0.478
Hypertension, (%)
76 (68.5)
43 (75.4)
33 (61.8)
0.187
Current smoker, (%)
20 (18.0)
11 (19.3)
9 (16.4)
0.682
Hypercholesterolemia, (%)
59 (53.2)
39 (68.4)
20 (36.4)
0.002
Coronary vessel disease, (%)
59 (53.2)
57 (100.0)
2 (3.6)
<0.001
Atrial fibrillation, (%)
56 (50.5)
28 (49.1)
28 (51.9)
0.774
Left ventricular ejection faction
0.802
>40%, (%)
27 (32.7)
18 (32.7)
19 (35.8)
30-40%, (%)
39 (36.4)
21 (38.2)
18 (34.0)
<30%, (%)
32 (29.9)
16 (29.1)
16 (30.2)
Nt-proBNP, pg/ml (IQR)
1120 (443-2632)
1353 (449-3105)
851 (431-2117)
0.790
eGFR, ml/min/1.73m2 (IQR)
45.9 (35.0-54.7)
38.9 (32.2-50.2)
52.4 (41.9-59.9)
0.823
CRP, mg/dl (IQR)
0.36 (0.18-0.71)
0.32 (0.18-0.66)
0.37 (0.16-0.83)
0.520
Categorical data are presented as counts and percentages, continuous as median and IQR (interquartile range). Categorical data are analyzed using the chi-square test, continuous data using the Kruskal-Wallis test.
